GBC Blog

LabCorp Announces the Launch of the Epi proColon® Test for Colorectal Cancer Screening First FDA-Approved Blood-Based Colorectal Cancer Test Offers Alternative for Patients Non-Compliant with Existing Screening Options [Original post] May 09, 2016 08:45 AM Eastern Daylight Time BURLINGTON, N.C.–(BUSINESS WIRE)–Laboratory Corporation of America® Holdings (LabCorp®) (NYSE: LH) today announced the launch of Epi proColon®,…

IMS Health Holdings, Inc. (NYSE:IMS) and Quintiles Transnational Holdings Inc. (NYSE:Q) announced today that their respective boards of directors approved a definitive merger agreement, pursuant to which the companies will be combined in an all-stock merger of equals transaction. The merged company will be named Quintiles IMS Holdings, Inc. Based on the closing of IMS…

Epigenomics AG: China FDA names Epigenomics’ blood-based Septin9 colorectal cancer test a most innovative medical product for 2015 Berlin (Germany) and Germantown, MD (U.S.A.), May 2, 2016 – Epigenomics AG (Frankfurt Prime Standard: ECX, OTCQX: EPGNY), the German-American cancer molecular diagnostics company, announced today that the China Food and Drug Administration (CFDA) has named the…

From LABIOTECH.EU http://labiotech.eu/epigenomics-epiprocolon-interview-blood-test-cancer-colon-diagnostics-us/ We met the Biotech that just launched the First & Only Blood Test for Colorectal Cancer in the US 14/04/2016 Colorectal cancer is the second biggest Cancer killer in the US. This sad figure could be dramatically improved if the diagnostic would be more effective. A problem Berlin-based Epigenomics want to solve and just got…

Apr. 13, 2016 2:19 PM ET In pulling off the almost unheard-of feat of successfully appealing against an FDA rejection, Epigenomics (OTCQX:EPGNF) today got full approval for its twice-denied colon cancer blood test, saw its share price rise 24%, and shone a light on some rather odd behavior from the US regulator. “We had a…

12-April-2016 Curetis AG / Curetis Publishes Full-Year 2015 Financial Results and Introduces 2016 Guidance . Processed and transmitted by NASDAQ OMX Corporate Solutions. The issuer is solely responsible for the content of this announcement. – Company successfully completed IPO on Euronext Amsterdam and Euronext Brussels, raising EUR 44.3 million  – Accelerated global commercialization lays strong…

http://www.japantimes.co.jp/news/2016/04/12/national/science-health/massive-whole-genome-study-finds-six-types-of-liver-cancer/#.Vw5qsJMrIUE

BioChain Acquires China Rights To Epigenomics AG Lung Cancer IVD [4/6/2016] BioChain, a US-China diagnostics/genomics tools company, has in-licensed China rights to a novel blood-based lung cancer diagnostic test from Epigenomics of Germany. BioChain will conduct China clinical trials for approval of the test in China and then commercialize it. In 2013, BioChain and Epigonomics…

View press release here: http://www.prnewswire.com/news-releases/cryoport-chosen-to-provide-cold-chain-logistics-support-to-proteogenex-300245387.html

Epigenomics Enters Agreement with Biochain on Lung Cancer Test for China March 30, 2016 Epigenomics AG : * Enters strategic license and development agreement with Biochain on novel, blood-based lung cancer test for China * Will receive undisclosed upfront, milestone and minimum annual payments as well as mid single-digit royalty on future revenues * Biochain…